5HJG
Crystal Structure of Human Transthyretin in Complex with Tetrabromobisphenol A (TBBPA)
5HJG の概要
| エントリーDOI | 10.2210/pdb5hjg/pdb |
| 関連するPDBエントリー | 1f41 |
| 分子名称 | Transthyretin, 4,4'-propane-2,2-diylbis(2,6-dibromophenol), SODIUM ION, ... (4 entities in total) |
| 機能のキーワード | transport protein, thyroxine binding, tetrabromobisphenol a complex |
| 由来する生物種 | Homo sapiens (Human) |
| 細胞内の位置 | Secreted: P02766 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 28665.45 |
| 構造登録者 | Begum, A.,Iakovleva, I.,Brannstrom, K.,Zhang, J.,Andersson, P.,Olofsson, A.,Sauer-Eriksson, A.E. (登録日: 2016-01-13, 公開日: 2016-05-04, 最終更新日: 2024-01-10) |
| 主引用文献 | Iakovleva, I.,Begum, A.,Brannstrom, K.,Wijsekera, A.,Nilsson, L.,Zhang, J.,Andersson, P.L.,Sauer-Eriksson, A.E.,Olofsson, A. Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer. Plos One, 11:e0153529-e0153529, 2016 Cited by PubMed Abstract: Amyloid formation of the human plasma protein transthyretin (TTR) is associated with several human disorders, including familial amyloidotic polyneuropathy (FAP) and senile systemic amyloidosis. Dissociation of TTR's native tetrameric assembly is the rate-limiting step in the conversion into amyloid, and this feature presents an avenue for intervention because binding of an appropriate ligand to the thyroxin hormone binding sites of TTR stabilizes the native tetrameric assembly and impairs conversion into amyloid. The desired features for an effective TTR stabilizer include high affinity for TTR, high selectivity in the presence of other proteins, no adverse side effects at the effective concentrations, and a long half-life in the body. In this study we show that the commonly used flame retardant tetrabromobisphenol A (TBBPA) efficiently stabilizes the tetrameric structure of TTR. The X-ray crystal structure shows TBBPA binding in the thyroxine binding pocket with bromines occupying two of the three halogen binding sites. Interestingly, TBBPA binds TTR with an extremely high selectivity in human plasma, and the effect is equal to the recently approved drug tafamidis and better than diflunisal, both of which have shown therapeutic effects against FAP. TBBPA consequently present an interesting scaffold for drug design. Its absorption, metabolism, and potential side-effects are discussed. PubMed: 27093678DOI: 10.1371/journal.pone.0153529 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.4 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






